GSK's Nucala For COPD Needs Better-Defined Patient Population, US FDA Panel Says

 
• By Derrick Gingery

Unclear data on monoclonal antibody's efficacy caused many members of Pulmonary-Allergy Drugs Advisory Committee to vote against recommending approval.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers